Based on our proprietary understanding of cellular energy, we are a leading developer of novel therapies for neurological and neuromuscular diseases, as well as certain dermaceutical and nutraceutical products.
AREAS OF FOCUS
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease
©2008 Avicena® Group |